Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
暂无分享,去创建一个
Y. Ohe | K. Goto | M. Nishio | N. Yamamoto | R. Toyozawa | T. Seto | K. Nakagawa | Pingkuan Zhang | T. Hida | T. Kumagai | K. Kudou | T. Shimokawaji | T. Asato | T. Yoshida
[1] A. Shaw,et al. LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study , 2020 .
[2] Jie Yang,et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Ahn,et al. Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L. , 2020 .
[4] K. Venkatakrishnan,et al. Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced Non-Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] S. Digumarthy,et al. Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] Young Hak Kim,et al. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. , 2019, Lung cancer.
[7] Edward S. Kim,et al. Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] Edward S. Kim,et al. Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial , 2019, Annals of Oncology.
[9] N. Rizvi,et al. Management strategies for early onset pulmonary events associated with brigatinib. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] A. Valipour,et al. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. , 2019, Anti-cancer drugs.
[11] N. Pavlakis,et al. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] Edward S. Kim,et al. Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib. , 2019, Journal of Clinical Oncology.
[13] R. Doebele,et al. Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC). , 2019, Journal of Clinical Oncology.
[14] A. Shaw,et al. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Shaw,et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. , 2018, The Lancet. Oncology.
[16] C. Gridelli,et al. Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[17] Young Hak Kim,et al. Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9 , 2018, Cancer science.
[18] Xin Zhang,et al. Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis , 2018, Frontiers in Oncology.
[19] Kenneth L. Jones,et al. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer , 2018, Clinical Cancer Research.
[20] Robert Jones,et al. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) , 2018, Molecular Cancer.
[21] Young Hak Kim,et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial , 2017, The Lancet.
[22] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[23] Edward S. Kim,et al. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M Kieser,et al. Point estimation and p‐values in phase II adaptive two‐stage designs with a binary endpoint , 2017, Statistics in medicine.
[25] Serafino Pantano,et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.
[26] T. Clackson,et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models , 2016, Clinical Cancer Research.
[27] Lauren L. Ritterhouse,et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .
[28] T. Clackson,et al. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. , 2016, Journal of Medicinal Chemistry.
[29] Jean Mosser,et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.
[30] T. Clackson,et al. 1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] M. Ladanyi,et al. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[32] Derek Y. Chiang,et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.
[33] S. Digumarthy,et al. Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study. , 2018 .
[34] G. Scagliotti,et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.